中新网杭州2月15日电 题：外籍科学家在杭州"解码"大脑 作者 林波 曹丹 为天生失明者植入大脑芯片，绕过眼睛直接"看见"世界；通过颅内脑电信号解码，实现多语种直接交 流……这些看似科幻的场景，正是西湖大学工学院讲席教授、先进神经芯片中心学术领头人默罕默德· 萨万(Mohamad Sawan)团队的研究方向。 近日，默 十余年前，这位电气工程与生物医学交叉领域的专家，将研究方向从外周神经系统转向更为复杂的大 脑。他的团队致力于开发受大脑启发的"神经形态芯片"——这类芯片模仿神经元工作机制，既能从大脑 中记录并解码神经信号，也能通过电刺激或药物输送实现闭环调控，为脑部疾病干预提供新路径。 在可植入式与可穿戴式智慧医疗器械领域，萨万已作出系统性贡献。目前，其团队在神经信号记录精度 和系统集成方面的研究处于世界前沿水平。 萨万以先天性失明为例说，团队正在开发的视觉修复系统，不走常规的"眼睛—视神经—大脑"路径，而 是直接将芯片植入大脑视觉皮层，并与外部摄像头无线连接，搭建起全新的视觉传导通道。 "每个电极被刺激时，会产生一个光点。"萨万解释道，"一系列光点构成低分辨率但真实的图像，大脑 接收后会进行优化，从而为盲人 ...

格隆汇2月9日｜科大讯飞在互动平台表示，脑科学当前尚处于前瞻性研究阶段，公司会保持关注和适当 投入。 ...

Core Insights - Neuroscience has historically been viewed as a high-risk area in pharmaceutical R&D, particularly for conditions like Alzheimer's disease and schizophrenia, due to complex pathophysiological mechanisms leading to high failure rates [1] - Recently, there has been a notable shift as the neuroscience sector is gaining momentum, driven by commercial success in Alzheimer's treatments and advancements in technologies such as small molecules, RNAi, cell therapy, and AI [1][6] - The combination of technological breakthroughs and market confidence is prompting multinational corporations (MNCs) to engage in mergers, acquisitions, and collaborations, signaling a potential "gold rush" in neuroscience [1] Industry Trends - The number of clinical trials and transactions in the neuroscience field is increasing, with 138 new drugs currently undergoing 182 clinical trials for Alzheimer's disease, marking a 9% increase from 2024 [2] - Over the past five years, more than 200 new clinical trials have been initiated for Alzheimer's disease, depression, and Parkinson's disease, indicating a growing interest in these areas [5] Market Developments - Confidence in the sector is rising, particularly due to breakthroughs in Alzheimer's treatments, such as Biogen's Leqembi, which achieved sales of $214 million in 2024 and $121 million in Q3 2025, reflecting an 82% year-over-year increase [6] - The approval of diagnostic methods, such as the Elecsys® pTau181 blood test by Roche and Eli Lilly, is enhancing the efficiency of Alzheimer's diagnosis and treatment [7] Technological Innovations - Emerging technologies like brain-computer interfaces and brain stimulation devices are becoming part of the investment narrative in neuroscience, with companies like Neuralink and Synchron conducting human clinical trials [8] - Advances in biomarkers and imaging agents are improving patient stratification in drug development, enhancing predictability of treatment efficacy [8] Policy Support - Significant government investments in brain science initiatives, such as the U.S. "Brain Initiative" with over $4 billion funding from 2014 to 2023, and China's brain plan with a budget exceeding 5 billion yuan, are fostering growth in the sector [8] Treatment Paradigms - The treatment landscape for Alzheimer's is evolving, with new therapies targeting Tau proteins gaining prominence over traditional Aβ-targeting approaches [9] - Innovations in drug delivery methods, such as brain-penetrating antibodies and RNAi technologies, are redefining treatment boundaries in neuroscience [11][12] Conclusion - After decades of exploration, the neuroscience field is experiencing unprecedented research intensity and commercialization, marking the onset of a new "gold rush" in the industry [13]

Core Viewpoint - The company, Weining Health, has not yet established a presence in the brain-computer interface sector and is currently focused on providing AI models and related medical AI products primarily as tools for healthcare institutions and medical personnel to enhance efficiency and accuracy in digital and intelligent applications [1] Group 1 - The company has stated that it does not currently engage in any hardware or software business related to brain-computer interfaces [1] - The AI models and medical AI products offered by the company are aimed at improving the operational capabilities of healthcare providers rather than directly participating in the diagnosis and treatment of related diseases [1] - As of now, the company is unable to assess the role of its AI models in the field of brain science, as it has not received information on whether users have applied these products in the treatment of brain-related diseases [1] Group 2 - The company encourages stakeholders to monitor its regular reports and public communications for updates on the progress of its AI models and related medical AI products [1]

央视网消息（焦点访谈）：现实中，有些新技术、新产品刚刚出现的时候，由于缺少"第一个吃螃蟹的人"，应用案例少，应用效果也缺少验证支撑，导致它 们不太容易进入市场，出现"英雄无用武之地"的现象，有些"新技术"硬被拖成了"老技术"。去年11月7日，《关于加快场景培育和开放推动新场景大规模应 用的实施意见》发布，一个重要目的就是要解决类似这样一些问题。而场景就是把新技术、新产品、新业态放在一个具体情境中来应用、来验证，为新兴事 物提供展示应用的舞台，加快其产业化进程。那么，经过两个多月的加快实践，新场景大规模应用如何才能实现呢？ 舞台上整齐划一，跳出优雅舞姿；手术台上精准操作，完成精密骨科手术……这是被大家称赞的典型机器人，在公众眼里，它们聪明、灵活、敏捷。这些较 为成熟的机器人在不同领域大放光彩。不过，很多机器人在初生时，是这样的：翻跟头时零件掉落，踉踉跄跄；马拉松赛场上跌跌撞撞，摔跤不断。从踉踉 跄跄到优雅舞姿的过程，是机器人不断学习进步的过程。 学习可以让机器人迭代升级，不断进步。不过，在哪学则是个难题。位于安徽合肥的具身智能机器人数据采集训练场，被工作人员称为机器人"高级技校"。 场地按照真实工业与家庭场景， ...

Group 1: Semiconductor Industry - The semiconductor industry is currently facing systemic cost pressures, with companies like Zhongwei Semiconductor and Guoke Micro announcing price increases of 15%-50% for products such as MCU and Norflash due to supply chain constraints and rising costs [1][2] - The packaging and testing costs have significantly increased, particularly for standard products like MCU and Norflash, leading to longer delivery cycles and greater operational pressure on companies [2] - The demand for DRAM and NAND Flash from major manufacturers is driving up orders for storage testing companies, with price increases of up to 30% expected as capacity utilization approaches full load [2] Group 2: Natural Gas Market - A severe winter storm has caused natural gas prices in the U.S. to surge, with Henry Hub futures reaching $7.43 per million British thermal units, a 140% increase since January 16 [3] - Spot prices in the northeastern U.S. have skyrocketed to between $50 and $150 per million British thermal units due to the storm, which has resulted in significant fatalities [3] - Short-term oil prices are under pressure from tariff policies and OPEC+ production increases, but geopolitical risks and global demand resilience may support oil price stability [3] Group 3: Artificial Intelligence - DeepSeek has launched a new document recognition model, DeepSeek-OCR2, which features a self-developed visual encoder that enhances semantic understanding [4] - The AI application landscape is expected to accelerate significantly by late 2025 to early 2026, with major tech companies making strategic moves in the AI space [4] - The upcoming release of DeepSeek's V4 model is anticipated to create competitive pressure on overseas closed model vendors, potentially reshaping the global AI market [5] Group 4: Brain-Computer Interface - The Brain-Computer Interface (BCI) industry is transitioning from laboratory research to clinical and consumer applications, with significant policy support and technological advancements driving this shift [5] - The BCI has been included in China's "14th Five-Year Plan" as a key development area, with independent billing projects set to be established by 2025 [5] - Non-invasive BCI technologies are already in mass production for rehabilitation and focus training, with companies like Neuralink planning to scale production of BCI devices [5] Group 5: Macro and Industry News - China Aviation Engine Corporation has outlined its strategic tasks for the "14th Five-Year Plan," focusing on accelerating the development of aviation engines and achieving technological self-reliance [6] - A major green hydrogen project in Inner Mongolia has undergone a significant capacity increase, now featuring 308 alkaline electrolysis cells and 152 PEM devices [7] - The National Energy Administration has established several standardization technical committees related to the hydrogen energy sector [7]

Core Viewpoint - The company plans to establish a specialized industry fund for brain-computer interfaces and brain science, with a total scale of 200 million yuan, to accelerate its strategic layout in this field [1] Group 1: Fund Details - The fund will be co-invested with professional investment institutions, with the company contributing 190 million yuan, accounting for 95% of the total committed capital [1] - The initial investment amount from the company is set at 50 million yuan, with the remaining contributions to be made based on project investment needs [1] Group 2: Investment Focus - The fund will target unlisted companies in the domestic and international brain-computer interface and brain science industry chain [1] - The aim is to enhance the company's industrial layout in brain-computer interfaces and neuroscience, promoting resource sharing and integration [1] Group 3: Strategic Goals - The fund seeks to achieve capital appreciation while serving the company's long-term strategic development goals [1] - The establishment of the fund is still pending approval from relevant authorities, and there are uncertainties regarding the smooth progress of investment projects [1]

Core Viewpoint - The article discusses the return of Chen Tianqiao, a prominent figure in the Chinese internet industry, who is now focusing on brain-computer interface (BCI) technology and artificial intelligence (AI) research, marking a significant shift in his career and investment strategy [4][15]. Group 1: Chen Tianqiao's Return and Investments - Chen Tianqiao announced a $1 billion investment in computing power to support global AI research, emphasizing his commitment to advancing scientific discovery through AI [4][15]. - He co-founded "Gestalt," the first domestic ultrasound brain-computer interface company in China, which aims to develop non-invasive BCI technology [8][9]. - Chen's approach contrasts with Elon Musk's invasive BCI strategy, focusing instead on a non-invasive method that poses fewer ethical and safety concerns [9][19]. Group 2: AI and Brain Science Integration - Chen Tianqiao's new company "Tanka" is defined as a communication platform integrating AI with long-term memory capabilities, aiming to redefine organizational management in the AI era [9][10]. - He believes that AI should execute tasks while humans take responsibility for outcomes, highlighting a shift in the role of leadership in organizations [9][11]. - The integration of brain science and AI is seen as a potential pathway to understanding human cognition and emotional regulation, creating new opportunities for innovation [20]. Group 3: Historical Context and Personal Journey - Chen's interest in brain science began after experiencing panic attacks during his peak career, prompting him to explore the workings of the human brain [12][13]. - Over the past decade, he has invested in brain science research, establishing the Tianqiao Brain Science Research Institute (TCCI) with a $1 billion donation, focusing on understanding and treating brain diseases [14][15]. - His return to the public eye is characterized by a long-term vision, aiming to build a comprehensive chain from basic research to commercial application in the fields of brain science and AI [19][20].

格隆汇1月12日丨上海临港(600848.SH)在互动平台表示，公司下属全资子公司上海临港浦江国际科技城 发展有限公司参股投资了上海临港司南生命科技有限公司，持有其20%股权。上海临港司南生命科技有 限公司主要负责司南生命科技超级孵化器、司南脑机智能超级孵化器的运营管理。其中司南脑机智能超 级孵化器是上海脑机接口未来产业集聚区的重要创新功能部分，专注于脑科学、脑机接口领域，基于前 沿技术概念验证、创新孵化、临床转化特点及创业难点提供专业化概念验证服务和企业孵化加速服务。 上海临港司南生命科技有限公司将构建一个贯穿"数据-算法-硬件-系统"全链条的技术协同创新体系，研 发大脑活动精准感知、干预、治疗和康复等方向的解决方案等。 ...

证券日报网讯 1月7日，苏州高新（600736）在互动平台回答投资者提问时表示，根据景昱医疗官网资 料显示，景昱医疗聚焦脑科学领域，研发并提供脑机接口DBS产品。有关景昱医疗具体情况请直接咨询 该企业。 ...